Tonix is developing innovative pharmaceutical products to address major public health challenges. In addition to Tonmya for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD, and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine.

Pharmaceutical

Tonix Pharmaceuticals

Tonix Pharmaceuticals' headquarters in New York, NY, United States

Description

People (7)

Jobs (0)

Other offices